全球肛裂治疗市场 – 行业趋势及 2030 年预测

肛裂治疗市场分析及规模

肛裂治疗市场增长的因素包括易患便秘的人群、久坐不动的生活方式以及辛辣、饱和和反式脂肪食物的消费。该地区肛瘘市场领域的不断进步最有可能在预测期内增加市场增长。竞争对手的不断增加、与胃肠道疾病相关的意识、产品发布和收购推动了市场增长。

 Data Bridge Market Research 分析了 2023-2030 年预测期内肛裂治疗市场的增长率。在上述预测期内，肛裂治疗市场的预期复合年增长率趋于 8.7% 左右。2022 年市场价值为 12.9623 亿美元，到 2030 年将增长至 25.265 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

肛裂治疗市场范围和细分

Market Definition

Anal fissure is also termed anal ulcer an anorectal disorder characterized by inflammation or tearing of lining of the lower rectum. It causes extreme pain and bleeding during bowel movement. The condition is not life threatening but considerably affects the quality of person’s life. This condition generally heals on its own in four to six weeks. The common treatments include dietary fibre, stool softeners, and creams to the affected area.

Anal Fissure Treatment Market Dynamics

Drivers

• Increasing Elderly Population and Unhealthy Lifestyle

On account of its increasing elderly population, the market is expected to grow at a highest speed. The Administration for Community Living states that the percentage of Americans 65 and older to be augmented to 21.6% by 2040 from 16% in 2019. The other primary factors causing the expansion of the market includes the wide adoption of sedentary lifestyle and a rise in the consumption of saturated and trans fats. Around 28% of adults or 1.4 billion people are living a sedentary lifestyle which is nearly more than 1 in 4 adults globally.

• Rising Demand of Oral Route of Administration

The oral segment is expected to have increasing market share by the end of 2031. Laxatives, painkillers, calcium channel blockers, stool softners are some of the oral drugs. Botulinum toxin A and nitroglycerin are some of the topical medications. As most of these pharmaceuticals are widely available over the counter, the oral treatment segment holds the highest market share. Laxatives are often used for treating childhood constipation. More than 3% of children worldwide suffer from functional constipation on the other hand, 10-23% of incidence are anticipated in North and South America. Thus, this boosts the market growth.

Opportunities

• Increasing Genetic Manufacturers and Healthcare Expenditure

Several technical improvements with new products being launched by the pharmaceutical and biotechnology industries each year due to the presence of several generic manufacturers. As per the National Investment Promotion & Facilitation Agency, the Indian pharmaceutical businesses produced more than 60,000 generic brands spanning 60 therapeutic areas, which includes generic drugs, API/bulk drugs, OTC medications, and others. In addition to this, increasing healthcare expenditure globally further increases the market growth. For instance, healthcare spending in China was around 5.35% in 2019 up from 5.07 in 2017. Thus, this boosts the market growth.

• Growing Product Launches and Awareness

The wide presence of competitors, awareness associated with GI diseases, product launches, and acquisitions increases the market growth. For instance, Cross Valley Health & Medicine celebrates National Colorectal Cancer Awareness Month every year on March. Every year, healthcare professionals take this month to provide their patients with extra education around diseases of the colon and rectum. People become more aware of diseases in the rectum as a result of such government initiatives and this is most likely to increase the market growth during the forecast period.

 Restraints/Challenges

• Lack of skilled professionals

The absence of qualified professionals who cannot treat the patients with suitable treatments could limit the market growth during the forecast period 2023-2030.

• High Cost of Treatment

The growing expenditure associated with the medications impede the market growth. These inhibitors cost high and people in the developing and underdeveloped countries, lead to the under treatment of several patients. This impedes the market growth.

This anal fissure treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anal fissure treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Anal Fissure Treatment Market         

COVID-19 对肛瘘治疗市场产生了重大影响。例如，根据 2021 年发表的题为“2019 年冠状病毒疾病时代肛肠疾病管理见解”的文章，在 COVID-19 大流行期间，肛瘘的治疗被大大推迟，这导致患者处于不舒服的境地。在许多情况下，根据对克罗恩病患者的先前研究，门诊直肠镜探查和引流管放置是其他选择。没有肛裂病史的患者也会因 COVID-19 期间的药物而出现该病的症状。根据同一来源，在接受过 COVID-19 治疗的患者中也出现了肛裂的发病率。因此，COVID-19 对肛瘘治疗市场产生了重大影响

近期发展

• 2022年，Ossium Health, Inc. 获得美国 FDA 对其 OSSM-001 的新药临床试验 (IND) 申请的接受，OSSM-001 是一种间充质干细胞 (MSC) 产品，用于治疗克罗恩病患者的难治性肛周瘘。
• 2022 年，武田发布了 INSPIRE 的首个六个月中期分析结果，其中两组接受 6 个月评估的患者中 65% 的患者出现临床缓解。INSPIRE 是一项欧洲观察性、多中心、上市后开放注册研究，旨在评估 Alofisel (darvadstrocel) 对克罗恩病 (CD) 和复杂性肛周瘘患者的真实世界有效性和安全性

全球肛裂治疗市场范围

肛裂治疗市场根据治疗、给药途径、应用、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

治疗

• 硝酸盐软膏
• 钙通道阻滞剂
• 肉毒杆菌注射
• 外科手术
• 其他的

给药途径

• 口服
• 主题
• 其他的

应用

• 括约肌间瘘
• 经括约肌瘘
• 括约肌上瘘
• 其他的

最终用户

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

肛裂治疗市场区域分析/见解

对肛裂治疗市场进行了分析，并根据上述治疗、应用、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

肛裂治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于研究区域患有炎症性肠病的患者人数众多、早期采用先进技术以及公共和私营部门的医疗保健支出不断增加，北美肛裂治疗市场在整个预测期内一直呈现积极增长。

由于仿制药公司的存在以及人们对肛门直肠疾病的认识不断提高，亚太地区占据了市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球肛裂治疗市场份额分析

肛裂治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对肛裂治疗市场的关注有关

肛裂治疗市场的主要参与者包括：

• Abbvie, Inc（美国）
• 诺华公司（瑞士）
• 梯瓦制药工业有限公司 (以色列)
• Troikaa（印度）
• RDD Pharma, Ltd（美国）
• 协和麒麟株式会社（日本
•  Cipla Inc.（美国）
• 益普生制药（法国）
• 赛诺菲（法国）
• 勃林格殷格翰国际有限公司（德国）
• 鲁冰花（印度）
• Bliss GVS（印度）
• SRS 生命科学（新加坡）
• Healthy Life Pharma Private Limited（印度）
• Geri-Care Pharmaceuticals Corp.（美国）

SKU-52858